Lunit preps Korean IPO led by NH Investment Bank

Lunit and NH Investment Bank announced today an agreement that NH Investment will be the lead underwriter for Lunit’s Korean IPO, aimed by 2020.

After the approval of Lunit’s medical AI software by Korea Ministry of Food and Drug Safety (MFDS) in August, Lunit is now paving its way toward the Korean market, along with the global expansion, beginning with upcoming installation at Seoul National University Hospital. Lunit is also currently undergoing US FDA and Europe CE clearance.

NH Investment Bank is one of the top investment banks in Korea, having been able to successfully drive IPOs of companies with proven high technology.

Contact us
Jussarang Lee Communications Manager
Jussarang Lee Communications Manager
About Lunit

Perfecting Intelligence, Transforming Medicine.

With AI, we aim to make data-driven medicine the new standard of care. We are especially focused on conquering cancer, one of the leading causes of death worldwide.

We develop AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients.


Lunit, abbreviated from “learning unit,” is an AI software company devoted to developing advanced medical image analytics and data-driven imaging biomarkers via cutting-edge deep learning technology.

Founded in 2013, Lunit has been internationally acknowledged for its advanced, state-of-the-art technology and its application in medical images. Lunit has been named by CB Insights as one of “AI 100” startups transforming healthcare industry.

Lunit's technology has been recognized at international competitions such as ImageNet (5th place, 2015), TUPAC 2016 (1st place), and Camelyon 2017 (1st place), surpassing top companies like Google, IBM, and Microsoft. Lunit is based in Seoul, South Korea.

Lunit
15th floor, 27 Teheran-ro 2-gil, Gangnam-gu,
Seoul, South Korea